Ali OZTURK, Bashar Mohammed Salih İBAHİM, Mehdi Meskini HAYDARLOU

Seroprevalence of hepatitis E virus infection in acute leukemia patients with allogeneic transplantation

Aim: Hepatitis E Virus (HEV) infection is an emerging threat in allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) recipients. The aim of this study was to determine the prevalence of HEV infection in patients with acute leukemia before and after the transplantation.Material and Methods: The study was carried out with the serum samples taken before and after the transplantation from patients (n=42) with acute leukemia, who were 4 months to 64 years of age and who had allogenic transplant at Gazi University Hospital. All samples were tested in terms of HEV-specific anti-IgG and IgM positive value by using ELISA kit.Results: While 1 (2.3%) of the samples that were included in the study was positive anti-HEV IgG before transplantation, it was found negative after the transplantation (58th month). Positive anti-HEV IgM was not found before and after the transplantation in the collected samples. The average age of the seronegative group was determined as 30.8 ± 33.1 for male and female, respectively. There was no statistically significant difference in terms of anti-HEV IgM positivity and anti-HEV IgG positivity compared with seronegative cases of seropositive cases.Conclusions: This study was conducted to determine the prevalence of HEV infection in allogeneic stem cell patients. With this study, the incidence and importance of HEV can be determined in these patients before and after transplantation. This study can also create an important epidemiological data for our country.

PDF

___

1. Voiculescu M, Iliescu L, Ionescu C, et al. A crosssectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and SouthEastern regions of Romania. J Gastrointestin Liver Dis 2010;19:43-8.
2. Wang T, Chen J, Zhang Q, et al. Prevalence of hepatitis G virus infection among 67,348 blood donors in mainland China. BMC public health 2019;19: 685.
3. Abravanel F, Lhomme S, El Costa H, et al. Rabbit hepatitis E virus infections in humans, france. Emerg Infect Dis 2017; 23:1191–3.
4. Liang H, Chen J, Xie J, Sun, et al. Hepatitis E virus serosurvey among pet dogs and cats in several developed cities in China. PLoS ONE 2014;9:e98068.
5. Tosone G, Simeone D, Sperat AM, et al. Epidemiology and pathogenesis of fulminant viral hepatitis in pregnant women. Minerva Ginecol 2018; 70:480-6.
6. Karin N, Barreiro P, Macías J, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis 2013;57:465- 8.
7. Chevallier P, Labopin M, Milpied N, et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant 2012;47:1442-7.
8. Czechowicz A, Weissman IL. Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement. Immunol Allergy Clin North Am 2010; 30:159-71.
9. Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem cells and cloning 2010;26:105- 17.
10. Swartling L, Nordén R, Samuelsson E, et al. Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2020;55:1255- 63.
11. Pischke S, Hartl J, Pas SD. et al. Hepatitis E virus: Infection beyond the liver? J Hepatol 2017;66:1082-95.
12. Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 2016; 7:901-6.
13. Tok B. Investigation of hepatitis E seroprevalance in different age groups in Istanbul. Master thesis, Istanbul Haydarpasa Numune Training and Research Hospital, Istanbul, 2006.
14. Teshale EH, Hu DJ. Hepatitis E: Epidemiology and prevention. World J Hepatol 2011;3:285-91.
15. Uçar E, Çetin M, Kuvandık C, et al. Hepatitis E virus seropositivity in hemodialysis patients in Hatay province, Turkey. Mikrobiyol Bul 2009;43:299-302.
16. Aydin K, Koksal I, Caylan R, et al. Investigation of hepatitis E seropositivity in two regions. II. National Viral Hepatitis Symposium, 1994. Ankara, Turkey, 151.
17. Khan AI, Salimuzzaman M, Islam T, et al. Nationwide hospital-based seroprevalence of hepatitis A and hepatitis E virus in Bangladesh. Ann Glob Health 2020;86:1-6.
18. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010;16:74-82.
19. Sharifipour S, Rad KD. Seroprevalence of hepatitis E virus among different age groups in Tehran, Iran. New Microbes New Infect 2020;34:1-6.
20. Ross J, Severson RK, Swensen AR, et al. Seasonal variations in the diagnosis of childhood cancer in the United States. Br J Cancer 1999; 81:549-53.